Impel Pharmaceuticals Inc. (IMPL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Impel Pharmaceuticals Inc. (IMPL) trades at $0.04 with AI Score 46/100 (Grade C). Impel Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on therapies for central nervous system diseases. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for IMPL: IMPL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMPL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMPL: 1/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Impel Pharmaceuticals Inc. (IMPL) Healthcare & Pipeline Overview
Impel Pharmaceuticals Inc. develops and commercializes therapies for central nervous system diseases, primarily focusing on nasal formulations. Their lead product, Trudhesa, addresses acute migraine, positioning them in a competitive neurology market with ongoing research into treatments for autism and Parkinson's disease.
What Is the Investment Thesis for IMPL?
Impel Pharmaceuticals presents a focused investment opportunity within the CNS therapeutics market. The primary value driver is Trudhesa, their FDA-approved treatment for acute migraine. Continued market penetration and sales growth of Trudhesa will be critical. The development and potential approval of INP105 for agitation in autism and INP107 for Parkinson's OFF episodes represent significant growth catalysts, expanding their target market and revenue streams. However, the company's negative profit margin of -1023.1% indicates a high level of spending relative to revenue, requiring careful monitoring of cash burn and future funding needs. Successful clinical trial outcomes and regulatory approvals for their pipeline products are essential for long-term value creation. The company's relatively small market cap also introduces volatility.
Based on FMP financials and quantitative analysis
IMPL Key Highlights
- Trudhesa is FDA-approved for the acute treatment of migraine, offering a novel nasal delivery method.
- INP105 is in development for acute treatment of agitation and aggression in autism spectrum disorder, addressing a significant unmet need.
- INP107 has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease, showing potential for improved motor function.
- The company's gross margin is 48.7%, indicating potential for profitability as revenue scales.
- The company has 160 employees, reflecting its commercial-stage operations and ongoing research and development efforts.
Who Are IMPL's Competitors?
IMPL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACOR Acorda Therapeutics, Inc. | $0.66 | -24.02% | 42 | |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.34 | -1.27% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.37 | +2.74% | $268M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMPL's Key Strengths?
- Proprietary nasal drug delivery technology (POD).
- FDA-approved product (Trudhesa) for acute migraine.
- Pipeline of product candidates targeting CNS disorders.
- Experienced management team.
What Are IMPL's Weaknesses?
- Negative profit margin (-1023.1%).
- Reliance on Trudhesa for revenue.
- Limited commercial infrastructure compared to larger pharmaceutical companies.
- Small market capitalization, leading to volatility.
What Could Drive IMPL Stock Higher?
- Clinical trial results for INP105 in autism agitation.
- Clinical trial results for INP107 in Parkinson's OFF episodes.
- Continued expansion of Trudhesa market share and sales growth.
- Potential partnerships and collaborations to accelerate product development.
What Are the Key Risks for IMPL?
- Financial-distress signal — its Altman Z-Score of -23.89 sits in the distress zone (elevated bankruptcy risk).
- Regulatory setbacks or clinical trial failures for pipeline products.
- Competition from established pharmaceutical companies and novel therapies.
- Dependence on the success of Trudhesa.
- High operating expenses and need for additional funding.
What Are the Growth Opportunities for IMPL?
- Expanding Trudhesa Market Share: Trudhesa, Impel's FDA-approved treatment for acute migraine, has significant growth potential. The migraine market is substantial, with millions of sufferers seeking effective relief. By increasing awareness among healthcare providers and patients, and by highlighting the benefits of nasal delivery, Impel can capture a larger share of this market. The company can also explore expanding Trudhesa's label to include additional indications or patient populations. Success in this area would drive revenue growth and establish Trudhesa as a leading migraine treatment.
- Advancing INP105 for Autism Agitation: INP105, Impel's nasal formulation of olanzapine for acute agitation in autism spectrum disorder (ASD), represents a significant growth opportunity. Agitation is a common and challenging symptom in ASD, and there is a need for rapid and non-invasive treatment options. Successful clinical trials and regulatory approval of INP105 would allow Impel to address this unmet need and tap into a growing market. The company can also explore expanding INP105's label to include other behavioral disorders characterized by agitation.
- Developing INP107 for Parkinson's OFF Episodes: INP107, Impel's nasal formulation of carbidopa/levodopa for Parkinson's OFF episodes, has the potential to improve the lives of Parkinson's patients. OFF episodes are characterized by a sudden loss of motor control, and there is a need for fast-acting treatments to restore function. The successful completion of clinical trials and regulatory approval of INP107 would allow Impel to address this unmet need and establish a presence in the Parkinson's disease market. The company can also explore developing additional formulations or delivery methods for carbidopa/levodopa.
- Strategic Partnerships and Collaborations: Impel can pursue strategic partnerships and collaborations to accelerate the development and commercialization of its product pipeline. Partnering with larger pharmaceutical companies can provide access to resources, expertise, and distribution networks. Collaborations with academic institutions and research organizations can facilitate the discovery and development of new therapies for CNS disorders. These partnerships can help Impel expand its reach and accelerate its growth.
- Expanding into New Therapeutic Areas: While Impel's current focus is on migraine, autism, and Parkinson's disease, the company can explore expanding into new therapeutic areas within the CNS market. There are many other neurological and psychiatric disorders with unmet needs, such as Alzheimer's disease, multiple sclerosis, and depression. By leveraging its expertise in nasal drug delivery and CNS drug development, Impel can develop innovative therapies for these disorders and diversify its product portfolio.
What Opportunities Does IMPL Have?
- Expanding Trudhesa market share.
- Successful clinical development and approval of INP105 and INP107.
- Strategic partnerships and collaborations.
- Expanding into new therapeutic areas within CNS disorders.
What Threats Does IMPL Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Patent challenges and intellectual property infringement.
- Economic downturn and reduced healthcare spending.
What Are IMPL's Competitive Advantages?
- Proprietary Precision Olfactory Delivery (POD) technology for nasal drug delivery.
- FDA approval for Trudhesa, providing a competitive advantage in the migraine market.
- Pipeline of product candidates targeting unmet needs in CNS disorders.
- Experienced management team with expertise in drug development and commercialization.
What Does IMPL Do?
Impel Pharmaceuticals Inc., founded in 2008 and headquartered in Seattle, Washington, is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients suffering from central nervous system (CNS) diseases. The company's core focus lies in utilizing its proprietary Precision Olfactory Delivery, or POD, technology to deliver drugs via the upper nasal cavity, potentially offering improved bioavailability and faster onset of action compared to traditional routes of administration. Impel's lead product, Trudhesa, is an upper nasal formulation of dihydroergotamine (DHE) approved for the acute treatment of migraine. Trudhesa represents a significant advancement in migraine therapy, offering a convenient and effective alternative for patients who may not respond well to oral medications or who experience nausea. In addition to Trudhesa, Impel is actively developing INP105, an upper nasal formulation of olanzapine, for the acute treatment of agitation and aggression in autism spectrum disorder (ASD). This product aims to provide a rapid and non-invasive treatment option for managing behavioral disturbances in ASD patients. Furthermore, Impel is advancing INP107, an upper nasal formulation of carbidopa/levodopa, for the treatment of OFF episodes in Parkinson's disease. INP107 has completed Phase IIa clinical trials, demonstrating its potential to improve motor function and reduce the duration of OFF episodes in Parkinson's patients. Formerly known as Impel NeuroPharma, Inc., the company changed its name to Impel Pharmaceuticals Inc. in April 2022, reflecting its broader focus on pharmaceutical development and commercialization. With a team of 160 employees, Impel is committed to addressing unmet needs in CNS disorders and improving the lives of patients through innovative nasal drug delivery solutions.
What Products and Services Does IMPL Offer?
- Develop and commercialize therapies for central nervous system (CNS) diseases.
- Utilize proprietary Precision Olfactory Delivery (POD) technology for nasal drug delivery.
- Offer Trudhesa, an upper nasal formulation of dihydroergotamine (DHE) for acute migraine treatment.
- Develop INP105, an upper nasal formulation of olanzapine for acute agitation in autism spectrum disorder (ASD).
- Develop INP107, an upper nasal formulation of carbidopa/levodopa for OFF episodes in Parkinson's disease.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Seek regulatory approvals from the FDA for their therapies.
How Does IMPL Make Money?
- Develop and commercialize pharmaceutical products for CNS disorders.
- Generate revenue through sales of Trudhesa and, potentially, future products.
- Invest in research and development to expand their product pipeline.
- Seek partnerships and collaborations to accelerate growth and expand market reach.
What Industry Does IMPL Operate In?
Impel Pharmaceuticals operates in the competitive biotechnology industry, specifically targeting the central nervous system (CNS) therapeutics market. This market is characterized by high unmet needs and significant growth potential, driven by an aging population and increasing prevalence of neurological disorders. The migraine market, addressed by Trudhesa, is a large and growing segment. Competition includes established pharmaceutical companies and other biotechnology firms developing novel migraine treatments, such as ACOR, AXDX, BLCM, CWBR, and CYTO. Impel's focus on nasal drug delivery offers a potential competitive advantage through improved bioavailability and patient convenience. The development of treatments for autism and Parkinson's disease positions Impel in additional high-growth areas within the CNS market.
Who Are IMPL's Key Customers?
- Patients suffering from migraine, autism spectrum disorder, and Parkinson's disease.
- Healthcare providers who prescribe and administer Impel's therapies.
- Pharmacies and distributors that supply Impel's products to patients.
How Impel Pharmaceuticals Inc. Is Valued
Relative to its peer group, IMPL's quantitative score of 46/100 is below the peer average of 67/100.
F-Score 4/9Financial Health
Impel Pharmaceuticals Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -23.89 places it in the distress zone, a signal of elevated financial risk.
IMPL Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, which often signals positive expectations.
- Community sentiment has shifted positively, with many traders discussing potential breakthroughs in their product pipeline.
- Analysts have noted increased interest in their innovative therapies, highlighting a growing recognition of their market potential.
- Recent partnerships and collaborations have sparked optimism about expanding their reach and enhancing their credibility in the industry.
Bear Case
- Concerns persist regarding the pace of product development, as delays could impact market competitiveness and investor confidence.
- Social sentiment shows a faction of traders worried about the volatility in the biotech sector, which could affect IMPL's stock stability.
- Negative commentary around regulatory hurdles has surfaced, leading to skepticism about the approval timeline for key products.
- Some community members express doubts about the company's ability to sustain momentum without significant revenue growth in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMPL Latest News
IMPL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMPL.
Price Targets
Wall Street price target analysis for IMPL.
IMPL MoonshotScore
What does this score mean?
The MoonshotScore rates IMPL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Leonard S. Paolillo
CEO
Leonard S. Paolillo serves as the Chief Executive Officer of Impel Pharmaceuticals Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on commercialization and strategic leadership. Prior to joining Impel, he held various leadership positions at pharmaceutical companies, overseeing product launches, market access strategies, and business development initiatives. He has a proven track record of driving revenue growth and building successful commercial organizations.
Track Record: Since becoming CEO, Leonard S. Paolillo has focused on the commercial launch and expansion of Trudhesa. He has also overseen the continued development of Impel's pipeline products, including INP105 and INP107. His strategic decisions have aimed to position Impel as a leader in nasal drug delivery for CNS disorders. He manages 160 employees.
IMPL Healthcare Stock FAQ
What does the AI Score mean for IMPL?
IMPL holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Impel Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on therapies for central nervous system diseases. Their lead product, Trudhesa, targets acute migraine, while they …
What does Impel Pharmaceuticals Inc. do?
Impel Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company utilizes its proprietary Precision Olfactory Delivery (POD) technology to deliver drugs via the upper nasal cavity, potentially offering improved bioavailability and faster onset of action.
What are the main risks for IMPL?
Impel Pharmaceuticals faces several risks inherent to the biotechnology industry. These include the potential for regulatory setbacks or clinical trial failures for its pipeline products, particularly INP105 and INP107. Competition from established pharmaceutical companies and novel therapies in the migraine and CNS markets also poses a threat.
What are the key factors to evaluate for IMPL?
Impel Pharmaceuticals Inc. (IMPL) holds an AI score of 46/100 (low). Not financial advice.
How frequently does IMPL data refresh on this page?
IMPL's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMPL's recent stock price performance?
Impel Pharmaceuticals Inc. (IMPL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary nasal drug delivery technology (POD). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMPL overvalued or undervalued right now?
Impel Pharmaceuticals Inc. (IMPL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IMPL before investing?
Before investing in Impel Pharmaceuticals Inc. (IMPL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding IMPL to a portfolio?
Key strength of Impel Pharmaceuticals Inc. (IMPL): Proprietary nasal drug delivery technology (POD). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Analyst ratings and price targets are based on consensus estimates and may not be indicative of future performance.
- The biotechnology industry is inherently risky, and investors should conduct their own due diligence before making any investment decisions.